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1. Introduction {#brb3700-sec-0005}
===============

Central nervous system inflammatory demyelinating disease (CIDD) is a term that encompasses a broad spectrum of diseases such as multiple sclerosis (MS), neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), and transverse myelitis. MS is a prototypic form of CIDD that has garnered great interest by researchers worldwide due to its high prevalence, young age of onset and chronicity, which results in a significant social burden (Adelman, Rane, & Villa, [2013](#brb3700-bib-0001){ref-type="ref"}). Recent understanding of the role of aquaporin‐4 (AQP4) antibodies in NMO has enhanced researcher attention in this field (Lennon et al., [2004](#brb3700-bib-0014){ref-type="ref"}). As a result, numerous papers were published regarding these diseases, and the clinical characteristics and treatment strategies were decided to some degree (Aleixandre‐Benavent et al., [2015](#brb3700-bib-0002){ref-type="ref"}; Wingerchuk & Carter, [2014](#brb3700-bib-0020){ref-type="ref"}). However, there is increased demand to stratify the current literature regarding idiopathic inflammatory demyelinating disease to serve as a guide to researchers.

Bibliometrics is a research method that analyzes citation frequencies and patterns of articles in a category of interest (Moed, [2009](#brb3700-bib-0016){ref-type="ref"}). Although there is some debate as to the association between the number of citations and the quality of the study, highly cited articles can indirectly represent the impact of a particular article on the scientific community and the trends in a specific field of research (Moed, [2009](#brb3700-bib-0016){ref-type="ref"}). The results of a citation analysis can suggest "classic lists" of articles in a specific field and "hints" about trends in citations within an area.

Although a few bibliometric studies have examined CIDD, the research objects were restricted to particular regions, time periods or subtypes of CIDD, particularly MS (Aleixandre‐Benavent et al., [2013](#brb3700-bib-0003){ref-type="ref"}, [2015](#brb3700-bib-0002){ref-type="ref"}; Araujo, Moreira, & Lana‐Peixoto, [2006](#brb3700-bib-0004){ref-type="ref"}; Gonzalez de Dios et al., [2013](#brb3700-bib-0009){ref-type="ref"}). The aim of this study was to identify and analyze the characteristics of the top 100 most frequently cited articles under the heading of "CIDD" worldwide. Considering the increased importance of NMO in this field and the relatively short time period in which NMO has been regarded as a distinct entity from MS due to its AQP4 antibody specificity, different treatment response and pathology (Wingerchuk et al., [2015](#brb3700-bib-0019){ref-type="ref"}), we separately suggested citation classics for NMO in this study.

2. Materials and Methods {#brb3700-sec-0006}
========================

The Web of Knowledge Journal Citation Reports Science Edition 2014 (Thomson Reuters, New York, NY, USA) was used to search for all journals that are listed under the categories "clinical neurology", "neuroscience" and "medicine, general & internal". We retrieved all articles that were cited more than 100 times in the selected journals using the Cited Reference Search option of the Science Citation Index Expanded of the ISI Web of Science database (January 1945--February 2016).

To find the CIDD‐related works among all the articles that had been cited more than 100 times in the three categories, we used following search terms: "multiple sclerosis", "demyelinating disease", "myelitis", "optic neuritis", "clinically isolated syndrome", "neuromyelitis optica", "Devic\'s disease", "Balo concentric sclerosis", "Schilder\'s diffuse sclerosis", "Schilder\'s disease", "diffuse myelinoclastic sclerosis", "Marburg multiple sclerosis", "acute disseminated encephalomyelitis", "solitary sclerosis", "acute hemorrhagic leukoencephalitis", "neuromyelitis optica‐immunoglobulin G (NMO‐IgG)", and "aquaporin‐4 antibody". The search terms for the citation classics on NMO included "neuromyelitis optica", "Devic\'s disease", "NMO‐IgG", and "aquaporin‐4 antibody". The original texts of all the searched articles were evaluated for their applicability. The citation classics on NMO were defined as articles that were cited more than 100 times ([Garfield](#brb3700-bib-0006){ref-type="ref"}). The lists of the 100 top cited articles on CIDD and the citation classics on NMO were obtained and analyzed for their characteristics: number of citations, year of publication, published journal, authorship, country and institution of origin, type of article, subject of article (e.g., MS, NMO, ADEM, ON, etc.) and main issues. The country and institution of origin was defined by the affiliation of the first author. If the first author had more than one affiliation, the affiliation of corresponding author was used. Two researchers independently reviewed the data (J.E.K and K.M.P) and any disagreements were decided by further discussion with another neurologist (J.S.B). This study did not need to be reviewed by an ethics committee since it performed a bibliometric analysis of existing published studies.

3. Results {#brb3700-sec-0007}
==========

3.1. Characteristics of the top 100 cited articles of CIDD {#brb3700-sec-0008}
----------------------------------------------------------

The list of the top 100 cited articles on CIDD are presented in Table [1](#brb3700-tbl-0001){ref-type="table-wrap"}. The average number of citations for the top 100 cited articles were 664 (range, 330--3,897). The articles were published between 1972 and 2011, and the majority of the articles were published after 1995 (Figure [1](#brb3700-fig-0001){ref-type="fig"}a). There were 64 articles that were cited more than 400 times, which is the criteria commonly used as the threshold for a citation classic ([Garfield](#brb3700-bib-0006){ref-type="ref"}). The most frequently cited article was about the recommended diagnostic criteria for MS by an international panel that was published by McDonald et al. in 2001 \[rank 1\]. The revision of the "McDonald Criteria", which was published by Polman et al. in 2005 \[rank 2\], was second highest most cited article (Table [1](#brb3700-tbl-0001){ref-type="table-wrap"}). Sixty‐four of the 100 articles originated in the United States of America (USA) and the United Kingdom (UK). The Institute of Neurology (London, UK), the Mayo Clinic (Minnesota, USA), the Cleveland Clinic Foundation (Ohio, USA) and the Free University Hospital (Amsterdam, the Netherlands) had the highest rankings for their contribution to the top 100 most cited articles (Table [2](#brb3700-tbl-0002){ref-type="table-wrap"}). The highly cited articles were published in 13 journals, which was led by *Brain* (*n* = 24) and closely followed by *The New England Journal of Medicine* (*n* = 21) (Table [S1](#brb3700-sup-0001){ref-type="supplementary-material"}). Fifty‐three authors were found to have contributed more than three articles on the list. Miller DH was the most prolific author for the 100 articles, followed by Weinshenker BG and Polman CH (Table [S2](#brb3700-sup-0001){ref-type="supplementary-material"}). Of the top 100 articles, 77 articles were original research articles and 23 articles were review articles or guidelines.
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###### 

Countries and institutions of origin for the citation classics in the field of central nervous system inflammatory demyelinating disease (a) and neuromyelitis optica (b)

                                                                                                          No. of Citation Classics
  ------------------------------------------------------------------------------------------------------- --------------------------
  \(a\) CNS inflammatory demyelinating disease                                                            
  Countries of origin                                                                                     
  USA                                                                                                     41
  UK                                                                                                      23
  The Netherlands                                                                                         9
  Italy                                                                                                   6
  Germany                                                                                                 5
  France                                                                                                  4
  Switzerland                                                                                             4
  Canada                                                                                                  3
  Austria                                                                                                 3
  Australia                                                                                               1
  Denmark                                                                                                 1
  Institutions of origin                                                                                  
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  Cleveland Clinic Foundation (Ohio, USA)                                                                 8
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  University of Cambridge (Cambridge, UK)                                                                 5
  Harvard Medical School (Boston, USA)                                                                    4
  Hôpital Neurologique (Lyon, France)                                                                     4
  University Hospital Basel (Basel, Switzerland)                                                          4
  Scientific Institute Ospedale San Raffaele, University of Milan (Milan, Italy)                          3
  University of California (San Francisco, USA)                                                           3
  Center for Brain Research, Medical University of Vienna (Vienna, Austria)                               2
  Montreal Neurological Institute and Hospital (Quebec, Canada)                                           2
  State University of New York School of Medicine, Buffalo and Buffalo General Hospital (New York, USA)   2
  University of South Florida College of Medicine (Florida, USA)                                          2
  \(b\) Neuromyelitis optica                                                                              
  Countries of origin                                                                                     
  USA                                                                                                     20
  UK                                                                                                      6
  Japan                                                                                                   5
  Germany                                                                                                 4
  Austria                                                                                                 2
  Italy                                                                                                   2
  Canada                                                                                                  1
  France                                                                                                  1
  Institutions of origin                                                                                  
  Mayo Clinic, Rochester (Minnesota, USA)                                                                 16
  Tohoku University (Sendai, Japan)                                                                       4
  University of Oxford (Oxford, UK)                                                                       3
  St George\'s, University of London (London, UK)                                                         2
  University of Heidelberg (Heidelberg, Germany)                                                          2

CNS, central nervous system; UK, United Kingdom; USA, United States of America.

John Wiley & Sons, Ltd

The most predominant subject of the 100 articles was MS (*n* = 85) and among these, 7 articles focused on evaluating prognostic factors (clinical, magnetic resonance imaging \[MRI\] features or treatment availability) to determine the conversion of clinically isolated syndrome to MS \[ranks 21,30,45,64,70,92,98 in Table [1](#brb3700-tbl-0001){ref-type="table-wrap"}\]. Two articles enrolled ADEM patients, which were mainly pediatrics, and discussed the clinical and MRI features of ADEM that can be used to differentiate ADEM from MS \[ranks 81a,88b in Table [1](#brb3700-tbl-0001){ref-type="table-wrap"}\]. Two articles enrolled patients with several subtypes of CIDD concomitantly and one of these articles was a randomized controlled trial that evaluated the effect of plasma exchange in acute central nervous system (CNS) inflammatory disease \[ranks 68,71 in Table [1](#brb3700-tbl-0001){ref-type="table-wrap"}\]. Only nine articles were about NMO \[ranks 10,12,17,22,34,72b,77,90a,95 in Table [1](#brb3700-tbl-0001){ref-type="table-wrap"}\], and two articles about ON \[ranks 36,41 in Table [1](#brb3700-tbl-0001){ref-type="table-wrap"}\] were also included in the list.

The main issues and their time trends of the highly cited articles are summarized in Table [3](#brb3700-tbl-0003){ref-type="table-wrap"} and Figure [2](#brb3700-fig-0002){ref-type="fig"}a. Among the original articles, the majority of the papers (*n* = 27) focused on treatment topics such as the effects of immunomodulatory drugs including intramuscular interferon β‐1a, glatiramer acetate, natalizumab, rituximab, fingolimod, mitoxantrone, alemtuzumab, monoclonal anti‐tumor necrosis factor antibody cA2, steroid, and plasma exchange \[ranks 6,9,11,15,18,19,23,25,28b,30,33,35,36,46,48,55,56,64,68,70,87,88a,90a,93a,93b in Table [1](#brb3700-tbl-0001){ref-type="table-wrap"}\]. Other common issues were neuroimaging features as evaluated by MRI, diffusion tensor imaging, magnetic resonance spectroscopy and positron emission tomography (*n* = 17). A considerable portion of the papers also discussed the pathological findings of CIDD (*n* = 16).

###### 

General issues discussed in the highly cited articles on central nervous system inflammatory demyelinating disease and neuromyelitis optica

  Category                                        No. of articles
  ----------------------------------------------- -----------------
  CNS inflammatory demyelinating disease          
  Epidemiology and natural history                11
  Clinical scoring                                1
  Diagnostic/prognostic biomarkers                
  Serological biomarkers                          3
  Neuroimaging                                    17
  Electrophysiology (visual evoked potential)     1
  Pathology                                       16
  Treatment                                       27
  Treatment‐related complications                 1
  Guideline/review/meta‐analysis                  23
  Neuromyelitis optica                            
  Epidemiology/natural history/clinical feature   9
  Diagnostic/prognostic biomarkers                
  Serological biomarkers                          14
  Neuroimaging                                    3
  Pathology                                       3
  Treatment                                       3
  Guideline/review/meta‐analysis                  5
  Basic research                                  4

CNS, central nervous system.

John Wiley & Sons, Ltd

![Time trends in categories of citation classics on central nervous system inflammatory demyelinating disease (a) and neuromyelitis optica (b). CIDD, Central nervous system inflammatory demyelinating disease; NMO, Neuromyelitis optica](BRB3-7-e00700-g002){#brb3700-fig-0002}

3.2. Citation classics of NMO {#brb3700-sec-0009}
-----------------------------

Using the cut‐off threshold of 100 citations, we found 41 citation classics for NMO (Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}). The mean number of citations of the citation classics was 291 (range, 102--1,317). All articles were published between 1976 and 2012 and there was a surge in the number of publications after 2006 (Figure [1](#brb3700-fig-0001){ref-type="fig"}b). This surge in publications corresponds to the publication of the top 2 cited articles, in which the NMO‐specific autoantibody (NMO‐IgG) was detected in the serum of NMO patients \[rank 2 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\] and was subsequently followed by the suggestion of revised diagnostic criteria that included NMO‐IgG positivity in the diagnosis \[rank 1 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\]. These two articles had a significant role in discriminating NMO from MS. There are eight different countries of origin for the citation classics (Table [2](#brb3700-tbl-0002){ref-type="table-wrap"}). USA (*n* = 20) had the largest number of articles, which was followed by the UK (*n* = 6), Japan (*n* = 5) and Germany (*n* = 4). The Mayo Clinic (Minnesota, USA) was the most active publishing institution for the NMO citation classics (Table [2](#brb3700-tbl-0002){ref-type="table-wrap"}). The citation classics were published in 13 journals, which was led by *Neurology* (*n* = 15), followed by *Brain* (*n* = 7), *Archives of Neurology* (*n* = 5) and *Annals of Neurology* (*n* = 3; Table [S1](#brb3700-sup-0001){ref-type="supplementary-material"}). Twenty‐four authors contributed 3 or more of the articles on the citation classics list. Weinshenker BG had the highest number of articles, followed by Wingerchuk DM, Pittock SJ, Lennon VA, and Lucchinetti CF (Table [S3](#brb3700-sup-0001){ref-type="supplementary-material"}). Among the 41 articles, 5 were review articles or guidelines \[ranks 1,4,28,29,40 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\], 1 was a case report \[rank 37 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\], and the remainder of the articles was original research articles. Four articles reported basic science studies \[ranks 14,16,17,20 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\]. The main issues discussed in the citation classics for NMO and their trends over time are summarized in Table [3](#brb3700-tbl-0003){ref-type="table-wrap"} and Figure [2](#brb3700-fig-0002){ref-type="fig"}b. The most frequently discussed topic among the citation classics was the serological markers, NMO‐IgG or AQP4 antibody. The original studies concerning the diagnostic and prognostic values of NMO‐IgG or the AQP4 antibody and their pathogenicity were frequently cited \[ranks 2,10,11,14,15,16,17,20,21,22,23,24,31,33,34,35,36,41 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\]. The second most commonly cited issues were related to the natural course and clinical features of NMO \[ranks 3,12,25,26,27,30,32,37,39 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\]. Other frequently cited issues included NMO pathology \[ranks 5,7,13 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\], the effect of various treatments (rituximab or prednisolone with azathioprine) \[ranks 8,18,19 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\], and MRI characteristics \[ranks 6,9,38 in Table [4](#brb3700-tbl-0004){ref-type="table-wrap"}\].

###### 

Citation classics on neuromyelitis optica

  Rank   Article                                                                                                                                                                                                  No. of citations
  ------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  1      Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;**66**:1485--9.                                               1,317
  2      Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;**364**:2106--12.                                       1,231
  3      Wingerchuk DM, Hogancamp WF, O\'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic\'s syndrome). Neurology 1999;**53**:1107--14.                                               886
  4      Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;**6**:805--15.                                                            757
  5      Lucchinetti CF, Mandler RN, McGavern D et al. A role for humoral mechanisms in the pathogenesis of Devic\'s neuromyelitis optica. Brain. 2002;**125**:1450--61.                                          587
  6      Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;**63**:390--6.                                             370
  7      Roemer SF, Parisi JE, Lennon VA et al. Pattern‐specific loss of aquaporin‐4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;**130**:1194--205.                   363
  8      Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;**64**;1270--2.                                          342
  9      Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;**63**:964--8.   338
  10     Takahashi T, Fujihara K, Nakashima I et al. Anti‐aquaporin‐4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;**130**:1235--43.                                    319
  11     Weinshenker BG, Wingerchuk DM, Vukusic S et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;**59**:566--9.                             307
  12     O\'Riordan JI, Gallagher HL, Thompson AJ et al. Clinical, CSF, and MRI findings in Devic\'s neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996;**60**:382--7.                                     276
  13     Misu T, Fujihara K, Kakita A et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;**130**:1224--34.                                            276
  14     Bradl M, Misu T, Takahashi T et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;**66**:630--43.                                                               266
  15     Pittock SJ, Lennon VA, de Seze J et al. Neuromyelitis optica and non‐organ‐specific Autoimmunity. Arch Neurol 2008;**65**:78--83.                                                                        240
  16     Bennett JL, Lam C, Kalluri SR et al. Intrathecal pathogenic anti‐aquaporin‐4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66:617--29.                                                       221
  17     Hinson SR, Pittock SJ, Lucchinetti CF et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;**69**:2221--31.                          219
  18     Jacob A, Weinshenker BG, Violich I et al. Treatment of neuromyelitis optica with rituximab retrospective analysis of 25 Patients. Arch Neurol 2008;65:1443--8.                                           212
  19     Mandler RN, Ahmed W, Dencoff JE. Devic\'s neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;**51**:1219--20.                          210
  20     Saadoun S, Waters P, Bell BA et al. Intra‐cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;**133**:349--61.    210
  21     Jarius S, Aboul‐Enein F, Waters P, Vincent A, Verkman AS, Papadopoulos MC. Antibody to aquaporin‐4 in the long‐term course of neuromyelitis optica. Brain 2008;**131**:3072--80.                         199
  22     Matsuoka T, Matsushita T, Kawano Y et al. Heterogeneity of aquaporin‐4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007;**130**:1206--23.                              181
  23     Matiello M, Lennon VA, Jacob A et al. NMO‐IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;**70**:2197--200.                                                                         180
  24     Waters P, Jarius S, Littleton E et al. Aquaporin‐4 antibodies in neuromyelitis Optica and longitudinally extensive transverse myelitis. Arch Neurol 2008;**65**:913--9.                                  176
  25     Wingerchuk DM, Weinshenker BG. Neuromyelitis optica---Clinical predictors of a relapsing course and survival. Neurology 2003;**60**:848--53.                                                             173
  26     Nakashima I, Fujihara K, Miyazawa I et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO‐IgG. J Neurol Neurosurg Psychiatry 2006;**77**:1073--5.               165
  27     Ghezzi A, Bergamaschi R, Martinelli V et al. Clinical characteristics, course and prognosis of relapsing Devic\'s Neuromyelitis Optica. J Neurol 2004;**251**:47--52.                                    163
  28     Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;**6**:383--92.                                                                160
  29     Sellner J, Boggild M, Clanet M et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;**17**:1019--32.                                                            144
  30     Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;**65**:1479--82.                                   143
  31     Paul F, Jarius S, Aktas O et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLos Med 2007;**4**:e133.                                                                             132
  32     de Seze J, Stojkovic T, Ferriby D et al. Devic\'s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002;**197**:57--61.                                                 130
  33     McKeon A, Lennon VA, Lotze T et al. CNS aquaporin‐4 autoimmunity in children. Neurology. 2008;**71**:93--100.                                                                                            130
  34     Waters PJ, McKeon A, Leite MI et al. Serologic diagnosis of NMO A multicenter comparison of aquaporin‐4‐IgG assays. Neurology 2012;**78**:665--71.                                                       128
  35     Jarius S, Franciotta D, Bergamaschi R et al. NMO‐IgG in the diagnosis of neuromyelitis optica. Neurology 2007:**68**:1076--7.                                                                            127
  36     Banwell B, Tenembaum S, Lennon VA et al. Neuromyelitis optica‐IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008;**70**:344--52.                                                  110
  37     April RS, Vansonnenberg E. A case of neuromyelitis optica (Devic\'s syndrome) in systemic lupus erythematosus. Clinicopathologic report and review of the literature. Neurology 1976;**26**:1066--70.    109
  38     Filippi M, Rocca MA, Moiola L et al. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic\'s neuromyelitis optica. Neurology 1999;**53**:1705--10.       108
  39     Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;**68**:603--5.                         105
  40     Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012;**11**:535--44.                                                                                                    103
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4. Discussion {#brb3700-sec-0010}
=============

In the current study, we identified and characterized the top 100 cited articles concerning CIDD. Using this bibliometric approach, we can examine the historical progress within a field of interest and inform researchers of the articles or authors that have had a significant impact on the field.

The majority of the top 100 frequently cited articles on CIDD were published during 1995--2009. This unequal distribution might reflect the natural life span of articles in a specific academic society. Typically, scientific articles begin to be cited 1 to 2 years after publication and reach a maximum between 3 and 10 years (Marx, Schier, & Wanitschek, [2001](#brb3700-bib-0015){ref-type="ref"}). After this period, the number of citations for a particular article gradually decrease due to the "obliteration by incorporation" phenomenon, where the results of a citation classic are absorbed into the current knowledge (Garfield, [1987](#brb3700-bib-0007){ref-type="ref"}). Therefore, similar to the findings from other studies, a citation analysis can accurately capture the true impact of articles published within the last 10--20 years. Only 3 of the top 100 articles were published in 2010--2016. This result does not suggest that the recently published articles were less important, but indicates that insufficient time has elapsed to accumulate a large number of citations. Therefore, it is important to not only examine the absolute number of citations of an article but also the entire list of published articles to avoid overlooking critical works in that field. For example, the article describing the diagnostic criteria for MS that was published in 1976, which ranked 69 in our list, did not have less influence on researchers studying MS than the study on the McDonald criteria, which was published later and had the top rank in our study. The distribution of publication years of the NMO citation classics showed a somewhat different pattern. The number of citation classics abruptly increased after 2006. Before the detection of NMO‐specific antibodies (NMO‐IgG and AQP4‐antibody), NMO was regarded as a rare form of MS. "Optico‐spinal MS" was historical used to describe this unique phenotype (Kuroiwa & Shibasaki, [1976](#brb3700-bib-0013){ref-type="ref"}). However, the publication of revised NMO diagnostic criteria in 2006 that included MRI diagnostic criteria according to the length of the spinal cord lesion and the detection of the AQP4 antibody led many researchers to distinguish NMO from MS (Wingerchuk, Lennon, Pittock, Lucchinetti, & Weinshenker, [2006](#brb3700-bib-0021){ref-type="ref"}), which increased the importance of investigating NMO specifically. This conceptual change in NMO diagnosis for several decades might be indirectly reflected in our study.

About two thirds of articles in both lists (CIDD and NMO) originated from USA and United Kingdom. The overwhelming influence of these two countries can also be found in other clinical disciplines. These findings might be explained by the larger community of specialists, the availability of research funds and organized support in this area and the tendency of American/British researchers to cite local papers. In addition to these two countries, the Netherlands, Italy and Germany produced a relatively large number of highly cited articles on CIDD. Japan was the only non‐western country that had a significant number of NMO citation classics, which might reflect the ethnic predilection of NMO in Asia and the research efforts of the Institute of Tohoku University (Kira, [2003](#brb3700-bib-0011){ref-type="ref"}).

Journal impact factor is considered a representative metric for the influence of that journal in the associated scientific field (Garfield, [2006](#brb3700-bib-0008){ref-type="ref"}). Eighty‐eight percent of the top 100 cited articles on CIDD were published in five major journals with high impact factors: *Brain, The New England Journal of Medicine, Neurology, Annals of Neurology,* and *The Lancet*. However, not all of the frequently cited articles were published in high impact factor journals, but were published in journals with rich histories. The lead high impact factor journals were the same for the NMO citation classics list as for the CIDD list. However, the number of the journals in the Web of Science category "medicine, general & internal" was higher in the CIDD list than the NMO list.

Six of the articles among top 10 most cited articles on CIDD were about proposed diagnostic criteria guidelines for MS or NMO or review articles concerning the pathogenesis or clinical definition of these two diseases. The significant influence of these guidelines to individual clinical or experimental studies is expected considering their essential use in clinical practice and research. Common issues among the CIDD articles focused on the results from randomized controlled trials on the use of immunomodulatory drugs, the pathogenesis of MS and the diagnostic and prognostic use of new neuroimaging technologies such as MRI. The most common issues among the NMO articles were related to the pathogenicity of NMO and the diagnostic/prognostic value of the NMO‐IgG or AQP4 antibodies. Articles discussing the treatment and neuroimaging issues surrounding NMO represented only a small portion of the current list, but is likely to grow fast based on the trends observed in MS over the last few decades.

The number of citation classics, which was defined as articles that received more than 400 citations ([Garfield](#brb3700-bib-0006){ref-type="ref"}), was 64 for the CIDD list. This number is slightly smaller than other neurological diseases (107 for Parkinson\'s disease and 89 for epilepsy; Ibrahim, Snead, Rutka, & Lozano, [2012](#brb3700-bib-0010){ref-type="ref"}; Ponce & Lozano, [2011](#brb3700-bib-0017){ref-type="ref"}). This might be influenced by differences in the number specialists who work in specific field or the portion of basic research publications for each disease. A recent paper presented the bibliometrics for all the research studies under the term "MS" (Aleixandre‐Benavent et al., [2015](#brb3700-bib-0002){ref-type="ref"}). This study had a different viewpoint and methodological approach from our study, which might explain the discordance between the results of the two studies. We analyzed the top 100 cited articles on CIDD published during an unlimited time period, but other researchers included whole articles published in the *Multiple Sclerosis Journal* and articles under the term "MS" in the Web of Science database during 2003--2012.

Our research has some limitations that should be considered. First, as aforementioned, temporal bias is inevitable in a bibliometric analysis. Older articles can be more or less cited due to increased opportunities to be cited over time and the "obliteration by incorporation" phenomenon (Bohannon & Roberts, [1991](#brb3700-bib-0005){ref-type="ref"}; Garfield, [1987](#brb3700-bib-0007){ref-type="ref"}). There were limited Internet resources for the articles published before 1990. Similarly, the impact of recently published compelling articles can be underestimated due to an insufficient amount of time to accumulate citations. Use of other citation indices, such as average citations per year or time duration of high citations, may overcome this temporal bias, although results may still be influenced by the period of analysis. Second, several important articles might have been missed from our lists including articles published in journals in categories such as "immunology" or "pediatrics". However, the proportion of articles in these categories was modest among the MS original research articles (Aleixandre‐Benavent et al., [2015](#brb3700-bib-0002){ref-type="ref"}). Third, incomplete citation bias might impact the results. Incomplete citations include various conscious or unconscious bias that arise from self‐citations, omissions, native language preponderance and the tendency to cite review articles or high impact factor journals (Ponce & Lozano, [2011](#brb3700-bib-0017){ref-type="ref"}; Seglen, [1997](#brb3700-bib-0018){ref-type="ref"}). Furthermore, there are other databases such as Scopus and Google Scholar that can be used for citation analysis. Selected search engines may have influenced the results (Kulkarni, Aziz, Shams, & Busse, [2009](#brb3700-bib-0012){ref-type="ref"}).

Here, we presented a detailed list of the top 100 cited articles for the topic CIDD and also separately propose citation classics for NMO using bibliometric methods. A strength of our research is that we included all types of articles published worldwide during an unrestricted time period. Although the citation rate does not directly represent the quality of the study, it is one marker used to recognize the importance of studies in the scientific community. We can trace scientific progress and identify seminal articles in a specific field by citation analysis.
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